Closed at 8c - up 50% on the day - it did have an intraday high of 9.2c...
PAT-DX1 Crosses Blood Brain Barrier to Reduce Brain Tumour Size
Melbourne, Australia; February 28, 2018: Patrys Limited (ASX: PAB), a therapeutic antibody development company, is pleased to announce further pre‐clinical data for its drug candidate PAT‐DX1, Patrys’ humanized version of the 3E10 anti‐DNA antibody. Drs James Hansen and Jiangbing Zhou of Yale University have shown that PAT DX1 administered by tail vein injection crossed the blood brain barrier to significantly reduce tumour size in an orthotopic animal model of glioblastoma using human tumor explants. Evaluation of brain sections showed that the glioblastoma tumours in mice treated with PAT‐DX1 were more than 40% smaller than the comparable tumours in control mice.
the trading today seems to indicate that there is a fair bit of confidence swirling around PAB at the moment.
Drs James Hansen and Jiangbing Zhou of Yale University have shown that PAT-DX1 administered by tail vein injection significantly improved survival in an orthotopic animal model of MGMT-unmethylated glioblastoma derived from human tumour explants. Based on groups of seven mice in each study arm, mice treated with PAT-DX1 showed a median survival of 87 days, more than 20% longer than controls (median 72 days). Mean survival data reflected these trends (83 days ± 3.2 days for PAT-DX1 treated mice, 71 days ± 1.2 days for controls). Statistical analysis indicated a significant difference between the two groups, with P value = 0.004. No toxicity associated with DX1 treatments was observed.
Nearly de ja Vue 3 years on...Patrys Limited has shot up in price today. So far it's up 33.33% to 2.8c. I must admit to not having heard about this company before.
a lot of volume went through this week
https://www.patrys.com/site/in-the-news/Bioshares874rbpPAB_18 December 2020.pdf
Looking for it to continue into January
Got some PABO @3c on Friday. The 2.4c strike and an expiry of June 23 puts them almost in the money with the heads closing at 4.9c.PAB as been granted another U.S. patent, “Cell-penetrating anti-DNA antibodies and uses thereof inhibit DNA repair”. This new patent provides protection until August 2033.
View attachment 122165
PAB now has a total of six patents, one each in Europe, Japan, China, and three in the U.S. I like the way this company is progressing its intellectual property portfolio. I'm not a huge fan of biotechs, but I like this company and think 2021 might well be a turning point year for them. Cancer is a big deal, and PAB may just be developing a viable treatment.
Pretty penny, trending constant highs, what gives?
View attachment 126413
(QUOTE) greggles...PAB appears to be forming a cup and handle pattern. No news of note this month other than a Corporate Overview released on 12 June. Nice steady uptrend over the last few weeks.
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?